Regulus Therapeutics (NASDAQ:RGLS) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Regulus Therapeutics (NASDAQ:RGLSGet Rating) in a research report issued on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Regulus Therapeutics in a research report on Monday, May 9th.

Shares of NASDAQ:RGLS opened at $0.26 on Tuesday. The company has a market cap of $37.46 million, a price-to-earnings ratio of -0.86 and a beta of 2.18. The company has a 50-day moving average price of $0.24 and a 200-day moving average price of $0.27. The company has a current ratio of 12.32, a quick ratio of 12.32 and a debt-to-equity ratio of 0.07. Regulus Therapeutics has a 12 month low of $0.16 and a 12 month high of $1.05.

Regulus Therapeutics (NASDAQ:RGLSGet Rating) last issued its quarterly earnings data on Thursday, May 12th. The biopharmaceutical company reported ($0.05) EPS for the quarter, meeting the consensus estimate of ($0.05). During the same quarter in the prior year, the company earned ($0.08) EPS. As a group, research analysts forecast that Regulus Therapeutics will post -0.22 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Federated Hermes Inc. purchased a new stake in Regulus Therapeutics in the first quarter worth about $8,656,000. DAFNA Capital Management LLC purchased a new stake in Regulus Therapeutics in the fourth quarter worth about $1,750,000. Asymmetry Capital Management L.P. grew its holdings in Regulus Therapeutics by 94.9% in the fourth quarter. Asymmetry Capital Management L.P. now owns 2,731,044 shares of the biopharmaceutical company’s stock worth $860,000 after purchasing an additional 1,329,553 shares during the period. Vanguard Group Inc. grew its holdings in Regulus Therapeutics by 21.4% in the first quarter. Vanguard Group Inc. now owns 3,678,334 shares of the biopharmaceutical company’s stock worth $1,096,000 after purchasing an additional 648,121 shares during the period. Finally, Morgan Stanley grew its holdings in Regulus Therapeutics by 206.0% in the second quarter. Morgan Stanley now owns 499,625 shares of the biopharmaceutical company’s stock worth $406,000 after purchasing an additional 336,374 shares during the period. Institutional investors own 47.06% of the company’s stock.

Regulus Therapeutics Company Profile (Get Rating)

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.

See Also

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.